BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 34114691)

  • 41. A limited sampling strategy for the estimation of 12-hour cyclosporine neoral area under the curve in Chinese cardiac transplant recipients.
    Wang CH; Ko WJ; Chou NK; Wang SS
    Transplant Proc; 2004 Oct; 36(8):2390-2. PubMed ID: 15561259
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of pharmacokinetics of Neoral and Sandimmune in stable pediatric liver transplant recipients.
    van Mourik ID; Thomson M; Kelly DA
    Liver Transpl Surg; 1999 Mar; 5(2):107-11. PubMed ID: 10071349
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cyclosporine monitoring in patients with renal transplants: two- or three-point methods that estimate area under the curve are superior to trough levels in predicting drug exposure.
    Primmett DR; Levine M; Kovarik JM; Mueller EA; Keown PA
    Ther Drug Monit; 1998 Jun; 20(3):276-83. PubMed ID: 9631924
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fasting Status and Circadian Variation Must be Considered When Performing AUC-based Therapeutic Drug Monitoring of Tacrolimus in Renal Transplant Recipients.
    Gustavsen MT; Midtvedt K; Robertsen I; Woillard JB; Debord J; Klaasen RA; Vethe NT; Bergan S; Åsberg A
    Clin Transl Sci; 2020 Nov; 13(6):1327-1335. PubMed ID: 32652886
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Report of the Canadian Neoral Renal Transplantation Study Group.
    Keown P; Landsberg D; Halloran P; Shoker A; Rush D; Jeffery J; Russell D; Stiller C; Muirhead N; Cole E; Paul L; Zaltzman J; Loertscher R; Daloze P; Dandavino R; Boucher A; Handa P; Lawen J; Belitsky P; Parfrey P
    Transplantation; 1996 Dec; 62(12):1744-52. PubMed ID: 8990355
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evolution of the therapeutic drug monitoring of cyclosporine.
    Citterio F
    Transplant Proc; 2004 Mar; 36(2 Suppl):420S-425S. PubMed ID: 15041378
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Best single time points to predict the area-under-the-curve in long-term heart transplant patients taking mycophenolate mofetil in combination with cyclosporine or tacrolimus.
    Mardigyan V; Giannetti N; Cecere R; Besner JG; Cantarovich M
    J Heart Lung Transplant; 2005 Oct; 24(10):1614-8. PubMed ID: 16210138
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Experience with therapeutic drug monitoring of cyclosporine.
    Abendroth D
    Transplant Proc; 2004 Mar; 36(2 Suppl):426S-429S. PubMed ID: 15041379
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Limited sampling strategy for cyclosporine (Neoral) area under the curve monitoring in pediatric kidney transplant recipients.
    Strong DK; Lai A; Primmett D; White CT; Lirenman DS; Carter JE; Hurley RM; Virji M; Ensom MH
    Pediatr Transplant; 2005 Oct; 9(5):566-73. PubMed ID: 16176411
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bayesian approach for the estimation of cyclosporine area under the curve using limited sampling strategies in pediatric hematopoietic stem cell transplantation.
    Sarem S; Li J; Barriere O; Litalien C; Théorêt Y; Lapeyraque AL; Nekka F
    Theor Biol Med Model; 2014 Sep; 11():39. PubMed ID: 25192585
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A 50% reduction in cyclosporine exposure in stable renal transplant recipients: renal function benefits.
    Etienne I; Toupance O; Bénichou J; Thierry A; Al Najjar A; Hurault de Ligny B; Le Meur Y; Westeel PF; Marquet P; François A; Hellot MF; Godin M
    Nephrol Dial Transplant; 2010 Sep; 25(9):3096-106. PubMed ID: 20299336
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Disposition of two oral formulations of cyclosporine in pediatric patients receiving hematopoietic stem cell transplants.
    Dupuis LL; Taylor T; Saunders EF
    Pharmacotherapy; 2006 Jan; 26(1):15-22. PubMed ID: 16509024
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Everolimus in combination with cyclosporin a as pre- and posttransplantation immunosuppressive therapy in nonmyeloablative allogeneic hematopoietic stem cell transplantation.
    Junghanss C; Rathsack S; Wacke R; Weirich V; Vogel H; Drewelow B; Mueller S; Altmann S; Freund M; Lange S
    Biol Blood Marrow Transplant; 2012 Jul; 18(7):1061-8. PubMed ID: 22182476
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Risk of infection according to the gamma globulin level in the 100 days following allogeneic stem cell transplantations.
    Lacombe V; Nunes Gomes C; Robin JB; Thépot S; François S; Cottin L; Ugo V; Dieu X; Abgueguen P; Daniel V; Giltat A; Hunault M; Riou J; Orvain C; Schmidt A
    Eur J Haematol; 2021 Oct; 107(4):489-496. PubMed ID: 34245060
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine.
    Kovarik JM; Kahan BD; Kaplan B; Lorber M; Winkler M; Rouilly M; Gerbeau C; Cambon N; Boger R; Rordorf C;
    Clin Pharmacol Ther; 2001 Jan; 69(1):48-56. PubMed ID: 11180038
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Correlation of C0 and C2 levels with cyclosporine side effects in kidney transplantation.
    Rodrigo E; Ruiz JC; Angeles de Cos M; Ruiz J; Gago M; Piñera C; Sánchez B; González-Cotorruelo J; Gómez-Alamillo C; Arias M
    Transplant Proc; 2009; 41(6):2328-31. PubMed ID: 19715910
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects.
    McSweeney PA; Niederwieser D; Shizuru JA; Sandmaier BM; Molina AJ; Maloney DG; Chauncey TR; Gooley TA; Hegenbart U; Nash RA; Radich J; Wagner JL; Minor S; Appelbaum FR; Bensinger WI; Bryant E; Flowers ME; Georges GE; Grumet FC; Kiem HP; Torok-Storb B; Yu C; Blume KG; Storb RF
    Blood; 2001 Jun; 97(11):3390-400. PubMed ID: 11369628
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term follow-up of pediatric transplant recipients: mycophenolic acid trough levels are not a good indicator for long-term graft function.
    Pape L; Ehrich JH; Offner G
    Clin Transplant; 2004 Oct; 18(5):576-9. PubMed ID: 15344963
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison and validation of limited sampling equations for cyclosporine area-under-the-curve monitoring calculations in pediatric renal transplant recipients.
    Charlebois JE; Lum BL; Cooney GF; Mochon M; Kaiser BA
    Ther Drug Monit; 1997 Jun; 19(3):277-80. PubMed ID: 9200767
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Calcineurin inhibitors in pediatric renal transplant recipients.
    Filler G
    Paediatr Drugs; 2007; 9(3):165-74. PubMed ID: 17523697
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.